The Pioneer in Regenerative Medicine
Cord Blood & Cord Tissue Banking
Learn why StemCyte has been the trusted leader around the world in Regenerative Medicine for 23+ years! Our goal is to consistently support the advancement of cord blood and cord tissue stem cell transplants and therapies, and deliver life-changing solutions to families around the world.
StemCyte was founded with a mission to advance the racial diversity of stem cell donations and storage and to increase global stem cell research.
Two StemCyte locations were in full operation and increasing its global inventory.
Singapore's Dr. Patrick Tan performed the world's first successful cord blood transplant for thalassemia major, and subsequently received a President's Award for his efforts.
StemCyte received AABB banking accreditation in the USA and Taiwan.
The world’s first Umbilical Cord Blood Transplantation Symposium was hosted by StemCyte at City of Hope National Cancer Hospital in Los Angeles, California.
StemCyte launched its private banking divisions in the USA and Taiwan.
StemCyte Taiwan received the world’s first grant for a non-US public bank and approval
from the Taiwan Food and Drug Administration (TFDA) for a Phase II IND clinical trial testing 12 patients diagnosed with Beta-Thalassemia Major.
StemCyte USA received a US Congressional earmark to diversify the United States' public cord bank inventory.
Dr. Wise Young, (Rutgers University) partnered with StemCyte to conduct clinical trials with the Company's newly-launched advanced therapeutics division.
StemCyte is the world’s first cord blood bank to receive accreditation for Allogeneic and Autologous banking from the Foundation for the Accreditation of Cellular Therapy (FACT).
StemCyte is the first private cord blood bank to become a Health Resources and Services Administration (HRSA) partner.
StemCyte expanded its operations to India and partnered with The Apollo Hospital Group and Cadila Pharmaceutical.
A US patent was submitted for stem cell brain damage treatments.
Two clinical trials were conducted:
The first, chronic stroke patients using autologous peripheral blood stem cells (CD34+). This trial had an 85% success rate.
The second was for the treatment of spinal cord injuries using mononuclear cells from HLA matched CBU from StemCyte’s inventory.
StemCyte applied for a method patent for the modification of cord blood stem cells that are resistant to HIV.
StemCyte and Dr. Young collaborated for a phase II spinal cord injury treatment.
StemCyte USA was awarded a U.S. Patent for its unique Plasma Depletion UCB Processing method.
A cord blood collection partnership was established between StemCyte and Sharp Healthcare in San Diego, California
The second phase of Dr. Young's spinal cord injury treatment was completed in 2012.
StemCyte received TFDA approval for its Phase II IND clinical trial using CD34+ from patients' peripheral blood for chronic stroke treatment.
During this year, a Chinese patent for the use of Lithium + UCB was awarded to StemCyte.
UC Davis and StemCyte partnered and developed a public cord blood bank program.
Kaiser and StemCyte partnered to create an innovative model for cord blood collection.
StemCyte applied for a US patent through partner Cell Research Corporation for storing and expanding mesenchymal and epithelial cells for therapeutic products.
StemCyte reached a significant milestone by shipping its 2,000th transplant unit.
StemCyte relocated to a new state-of-the-art facility in Baldwin Park, California.
StemCyte received a patent for Lithium Stimulation of Stem Cells Proliferation and growth factor production.
StemCyte was awarded a Japanese patent for stem cell screening of HIV infection.
StemCyte is the first hybrid cord blood bank to receive FDA approval for a Phase II clinical trial to treat spinal cord injuries.
StemCyte sponsored a Phase I Clinical Trial using cord blood stem cells to treat acute ischemic stroke.
The Future is So Bright